Back

Dual Pathways of Extracellular ATP Action in Cancer Cells: Purinergic Signaling Driven Senescence and Macropinocytic ATP Internalization

Stone, N.; Ward, R.; Bachmann, L.; Adhicary, S.; Nielsen, C. M.; Mehta, N.; Li, Y.; Zhang, H.; Song, J.; Prinz, S.; Chang, S.; Roberts, D.; Bergmeier, S.; Chen, X.; Shriwas, P.

2026-04-23 cancer biology
10.64898/2026.04.23.720363 bioRxiv
Show abstract

BackgroundOpportunistic nutrient uptake is a hallmark of cancer metabolism. Cancer cells upregulate macropinocytosis to acquire extracellular nutrients to support growth and stress adaptation. We previously showed that extracellular ATP (eATP) is internalized by macropinocytosis and promotes multiple cancer phenotypes. Here, we tested whether eATP uptake is prevalent across cancers and whether eATP also induces senescence through purinergic receptor (PR) signaling. MethodsIntracellular ATP (iATP) levels were measured following eATP exposure across multiple cancer cell lines. eATP internalization was visualized in vitro and in vivo using a non-hydrolyzable fluorescent ATP analog together with high-molecular-weight dextran as a macropinocytosis marker. Senescence was quantified using three SA-{beta}-galactosidase assays and flow cytometry. Pharmacologic inhibitors of macropinocytosis and purinergic receptors were used to define pathway dependence. Combination treatments with the glucose transporter inhibitor DRB18 and the senolytic navitoclax were evaluated for antiproliferative effects. ResultseATP produced dose- and time-dependent increases in iATP across diverse cancer cell types. Imaging demonstrated widespread macropinocytic internalization of ATP in vitro and in tumor xenografts. eATP induced senescence in NSCLC cells, confirmed by multiple {beta}-gal assays and flow cytometry. PR inhibition significantly reduced senescence, whereas macropinocytosis inhibition had minimal effect on senescence induction. ConclusionseATP acts through dual pathways in cancer cells: macropinocytic internalization that elevates iATP and PR signaling that drives senescence. Targeting metabolic uptake together with senolytic therapy may offer a novel anticancer strategy.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
British Journal of Cancer
42 papers in training set
Top 0.1%
10.5%
2
Cancers
200 papers in training set
Top 0.4%
10.2%
3
Molecular Cancer Therapeutics
33 papers in training set
Top 0.1%
8.5%
4
Cancer Research Communications
46 papers in training set
Top 0.1%
6.4%
5
Clinical Cancer Research
58 papers in training set
Top 0.2%
6.4%
6
PLOS ONE
4510 papers in training set
Top 33%
4.3%
7
BMC Cancer
52 papers in training set
Top 0.4%
4.2%
50% of probability mass above
8
Translational Oncology
18 papers in training set
Top 0.1%
3.6%
9
Scientific Reports
3102 papers in training set
Top 35%
3.6%
10
npj Precision Oncology
48 papers in training set
Top 0.4%
2.1%
11
Cancer Research
116 papers in training set
Top 1%
2.1%
12
Molecular Oncology
50 papers in training set
Top 0.4%
1.7%
13
Frontiers in Oncology
95 papers in training set
Top 2%
1.7%
14
EBioMedicine
39 papers in training set
Top 0.4%
1.7%
15
Neoplasia
22 papers in training set
Top 0.3%
1.5%
16
ACS Pharmacology & Translational Science
40 papers in training set
Top 0.6%
1.2%
17
iScience
1063 papers in training set
Top 21%
1.2%
18
Cancer Medicine
24 papers in training set
Top 1%
0.9%
19
Communications Biology
886 papers in training set
Top 21%
0.8%
20
JCI Insight
241 papers in training set
Top 7%
0.8%
21
Journal of Translational Medicine
46 papers in training set
Top 2%
0.8%
22
eLife
5422 papers in training set
Top 57%
0.8%
23
Molecular Biology of the Cell
272 papers in training set
Top 2%
0.8%
24
npj Breast Cancer
18 papers in training set
Top 0.2%
0.8%
25
Gastroenterology
40 papers in training set
Top 2%
0.8%
26
Aging
69 papers in training set
Top 3%
0.7%
27
International Journal of Cancer
42 papers in training set
Top 1%
0.7%
28
Frontiers in Immunology
586 papers in training set
Top 8%
0.7%
29
Annals of Oncology
13 papers in training set
Top 1%
0.7%
30
Oncotarget
15 papers in training set
Top 0.6%
0.6%